✦ LIBER ✦

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

✍ Scribed by Robertson, John FR; Ferrero, Jean-Marc; Bourgeois, Hugues; Kennecke, Hagen; de Boer, Richard H; Jacot, William; McGreivy, Jesse; Suzuki, Samuel; Zhu, Min; McCaffery, Ian; Loh, Elwyn; Gansert, Jennifer L; Kaufman, Peter A

Book ID: 121747622
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 229 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70026-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-Blind, Randomized Placebo Control

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

✍ Chia, Y.H.; Ma, C.X. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Phase II Trial of Fulvestrant With Metro

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

✍ Schwartzberg, Lee S.; Wang, Grace; Somer, Bradley G.; Blakely, L. Johnetta; Whee 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 276 KB

A randomized, double-blind, controlled s

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

✍ Iwata, Hiroji; Masuda, Norikazu; Ohno, Shinji; Rai, Yoshiaki; Sato, Yasuyuki; Oh 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 315 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Fulvestrant plus anastrozole or placebo

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

✍ Johnston, Stephen RD; Kilburn, Lucy S; Ellis, Paul; Dodwell, David; Cameron, Dav 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 459 KB